Stat5 tetramer formation is associated with leukemogenesis

Cancer Cell

Volumn 7, Issue 1, 2005, Pages 87-99

  Moriggl, Richard ^a   Sexl, Veronika ^b   Kenner, Lukas ^a   Duntsch, Christopher ^c   Stangl, Katharina ^a   Gingras, Sebastien ^c   Hoffmeyer, Angelika ^c   Bauer, Anton ^d   Piekorz, Roland ^e   Wang, Demin ^f   Bunting, Kevin D ^g   Wagner, Erwin F ^a   Sonneck, Karoline ^b   Valent, Peter ^b   Ihle, James N ^c   Beug, Hartmut ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d IMC UNIVERSITY OF APPLIED SCIENCES KREMS   (Austria)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; DNA; STAT5 PROTEIN; TETRAMER;

ANIMAL CELL; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CONTROLLED STUDY; DIMERIZATION; DISEASE ASSOCIATION; DNA BINDING; DNA DETERMINATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPECIES COMPARISON; WILD TYPE;

ANIMALIA; MURINAE;

EID: 19944431828     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.12.010     Document Type: Article

References (45)

1. Brivanlou A.H., Darnell J.E. Jr. Signal transduction and the control of gene expression. Science. 295:2002;813-818
2. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 109:2002;1139-1142
3. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8:2002;945-954
4. Bunting K.D., Bradley H.L., Hawley T.S., Moriggl R., Sorrentino B.P., Ihle J.N. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 99:2002;479-487
5. Cui Y., Riedlinger G., Miyoshi K., Tang W., Li C., Deng C.X., Robinson G.W., Hennighausen L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24:2004;8037-8047
6. Iavnilovitch E., Groner B., Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol. Cancer Res. 1:2002;32-47
7. John S., Vinkemeier U., Soldaini E., Darnell J.E. Jr., Leonard W.J. The significance of tetramerization in promoter recruitment by Stat5. Mol. Cell. Biol. 19:1999;1910-1918
8. Kelly J.A., Spolski R., Kovanen P.E., Suzuki T., Bollenbacher J., Pise-Masison C.A., Radonovich M.F., Lee S., Jenkins N.A., Copeland N.G., et al. Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J. Exp. Med. 198:2003;79-89
9. Kieslinger M., Woldman I., Moriggl R., Hofmann J., Marine J.C., Ihle J.N., Beug H., Decker T. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 14:2000;232-244
10. Kim H.P., Leonard W.J. The basis for TCR-mediated regulation of the IL-2 receptor alpha chain gene. Role of widely separated regulatory elements EMBO J. 21:2002;3051-3059
11. Leberbauer C., Boulmé F., Unfried G., Huber J., Beug H., Müllner E.W. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood. in press:2005
12. Lee H.C., Ye S.K., Honjo T., Ikuta K. Induction of germline transcription in the human TCR gamma locus by STAT5. J. Immunol. 167:2001;320-326
13. Lerner L., Henriksen M.A., Zhang X., Darnell J.E. Jr. STAT3-dependent enhanceosome assembly and disassembly. Synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene Genes Dev. 17:2003;2564-2577
14. Levy D.E., Gilliland D.G. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene. 19:2000;2505-2510
15. Lord J.D., McIntosh B.C., Greenberg P.D., Nelson B.H. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164:2000;2533-2541
16. Meyer W.K., Reichenbach P., Schindler U., Soldaini E., Nabholz M. Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription. J. Biol. Chem. 272:1997;31821-31828
17. Meyer T., Hendry L., Begitt A., John S., Vinkemeier U. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J. Biol. Chem. 279:2004;18998-19007
18. Mizuki M., Schwable J., Steur C., Choudhary C., Agrawal S., Sargin B., Steffen B., Matsumura I., Kanakura Y., Bohmer F.D., et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 101:2003;3164-3173
19. Moriggl R., Sexl V., Piekorz R., Topham D., Ihle J.N. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity. 11:1999;225-230. a
20. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., Hoffmeyer A., van Deursen J., Sangster M.Y., Bunting K.D., et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 10:1999;249-259. b
21. Nevalainen M.T., Xie J., Torhorst J., Bubendorf L., Haas P., Kononen J., Sauter G., Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 22:2004;2053-2060
22. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18:1999;4754-4765
23. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002. New surprises in the Jak/Stat pathway Cell. 109(Suppl):2002;S121-S131
24. Onishi M., Nosaka T., Misawa K., Mui A.L., Gorman D., McMahon M., Miyajima A., Kitamura T. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18:1998;3871-3879
25. Ota N., Brett T.J., Murphy T.L., Fremont D.H., Murphy K.M. N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat. Immunol. 5:2004;208-215
26. Primiano T., Baig M., Maliyekkel A., Chang B.D., Fellars S., Sadhu J., Axenovich S.A., Holzmayer T.A., Roninson I.B. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell. 4:2003;41-53
27. Ren S., Cai H.R., Li M., Furth P.A. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene. 21:2002;4335-4339
28. Santos S.C., Lacronique V., Bouchaert I., Monni R., Bernard O., Gisselbrecht S., Gouilleux F. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway. Oncogene. 20:2001;2080-2090
29. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., Lee C.K., Gerthner R., Kitamura T., Frantsve J., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell. 6:2000;693-704
30. Soldaini E., John S., Moro S., Bollenbacher J., Schindler U., Leonard W.J. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol. Cell. Biol. 20:2000;389-401
31. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer. 3:2003;650-665
32. Stoecklin E., Wissler M., Moriggl R., Groner B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol. Cell. Biol. 17:1997;6708-6716
33. Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Ida K., Hayashi Y. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 103:2004;1085-1088
34. Teglund S., McKay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., Ihle J.N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:1998;841-850
35. Tronche F., Opherk C., Moriggl R., Kellendonk C., Reimann A., Schwake L., Reichardt H.M., Stangl K., Gau D., Hoeflich A., et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev. 18:2004;492-497
36. Tsuruyama T., Nakamura T., Jin G., Ozeki M., Yamada Y., Hiai H. Constitutive activation of Stat5a by retrovirus integration in early pre-B lymphomas of SL/Kh strain mice. Proc. Natl. Acad. Sci. USA. 99:2002;8253-8258
37. Verdier F., Rabionet R., Gouilleux F., Beisenherz-Huss C., Varlet P., Muller O., Mayeux P., Lacombe C., Gisselbrecht S., Chretien S. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers. A distinct biochemical difference between STAT5A and STAT5B Mol. Cell. Biol. 18:1998;5852-5860
38. Vinkemeier U., Cohen S.L., Moarefi I., Chait B.T., Kuriyan J., Darnell J.E. Jr. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1. Interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites EMBO J. 15:1996;5616-5626
39. Vinkemeier U., Moarefi I., Darnell J.E. Jr., Kuriyan J. Structure of the amino-terminal protein interaction domain of STAT-4. Science. 279:1998;1048-1052
40. Wang D., Moriggl R., Stravopodis D., Carpino N., Marine J.C., Teglund S., Feng J., Ihle J.N. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J. 19:2000;392-399
41. Xi S., Zhang Q., Dyer K.F., Lerner E.C., Smithgall T.E., Gooding W.E., Kamens J., Grandis J.R. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. 278:2003;31574-31583. a
42. Xi S., Zhang Q., Gooding W.E., Smithgall T.E., Grandis J.R. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63:2003;6763-6771. b
43. Xu X., Sun Y.L., Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science. 273:1996;794-797
44. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer. 4:2004;97-105
45. Zhang X., Darnell J.E. Jr. Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J. Biol. Chem. 276:2001;33576-33581